Sold as Numbrino, Goprelto. Every FDA application for this active ingredient.
As of Nov 16, 2026, FDA lists 2 applications for Cocaine Hydrochloride (sold as Numbrino, Goprelto), first approved Dec 14, 2017, with 0 new uses approved and 1 published complete response letter.
| Low Intensity Focused Ultrasound in Cocaine Use DisorderCocaine Use Disorder (CUD) · University of Pennsylvania | Phase 1 | Not yet recruiting | Nov 10, 2026 |
| Examination of Transcranial Focused Ultrasound on Brain Activity in Adults With Cocaine Use DisorderCocaine Use Disorder (CUD) · Mary Phillips, MD MD (Cantab) | Not applicable | Not yet recruiting | Oct 1, 2026 |
| Open-label Feasibility Trial of HD-tDCS During Cognitive Behavioral Therapy for Cocaine Use DisorderCocaine Use Disorder · Virginia Commonwealth University | Not applicable | Recruiting | Sep 18, 2026 |
| Imaging Mitochondrial Complex-I in Cocaine Use Disorder: a [F-18]BCPP-EF PET StudyCocaine Use Disorder, Healthy Controls Group - Age and Sex-matched · Rajesh Narendran | Early phase 1 | Recruiting | Aug 19, 2026 |
| Effect of BG Versus RI on the Depth of WSLWhite Spot Lesions · Riphah International University | Not applicable | Not yet recruiting | Aug 18, 2026 |
| NEUROphysiology of CRACK Use Disorder in ITalyCrack Cocaine Use · Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo | Not applicable | Not yet recruiting | Jul 30, 2026 |
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use DisorderObesity, Methamphetamine Use Disorder · University of Texas Southwestern Medical Center | Phase 2 | Active, not recruiting | Jul 9, 2026 |
| The Impact of Cobenfy Maintenance on Cocaine's EffectsCocaine Use Disorder (CUD) · Joshua A. Lile, Ph.D. | Phase 1 / Phase 2 | Recruiting | Jun 3, 2026 |
| Dec 14, 2017 | GopreltoNDA 209963 · New formulation or manufacturer | Lxo Ireland | 2 | Marketed |
| Jan 10, 2020 | NumbrinoNDA 209575 · TYPE 7 | Omnivium Pharms | 1 | Marketed |
| Letter | Product | Now |
|---|---|---|
| Jul 20, 2018 | Cocaine HydrochlorideClinical, Nonclinical | Approved |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA